The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential

Advanced Drug Delivery Reviews

Volumn 10, Issue 1, 1993, Pages 91-114

  Katre, Nandini V ^a  

^a NONE

Author keywords

Drug delivery; Pharmaceutical applications; Pharmacokinetics; Polyethylene glycol; Protein modification; Protein polymer adducts

Indexed keywords

CHEMICAL REACTIONS; CONTROLLED DRUG DELIVERY; DNA; POLYETHERS; POLYMERS; PROTEINS; RECOMBINANT DNA TECHNOLOGY;

COVALENT CONJUGATION; POLYETHYLENE GLYCOLS; THERAPEUTIC POTENTIAL;

DRUG PRODUCTS;

ALBUMIN; ANTIBODY; BETA INTERFERON; CARBOXYMETHYLCELLULOSE; DEXTRAN; DRUG CARRIER; LIPOSOME; MACROGOL; METHOTREXATE; OLIGOSACCHARIDE; POLYACRYLIC ACID; POLYALANINE; POLYMALEIC ACID; POLYMER; POLYVINYL ALCOHOL; POVIDONE; PROTEIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECOMBINANT DNA TECHNOLOGY; REVIEW; TECHNIQUE;

EID: 0027253357     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(93)90005-O     Document Type: Review

References (125)

1. The biologic activity of water-soluble polymers
2. Bioactive polymeric systems; an overview
3. Laboratory synthesis of polyethylene glycol derivatives
4. Response of dogs to repeated intravenous injection of polyethylene glycol 4000
5. Toxicology of polyethylene glycols
6. Anaphylaxis to polyethylene glycol (PEG) in a multivitamin tablet
7. Immediate and delayed allergic contact reactions to polyethylene glycol
8. Soluble polymer-enzyme adducts
9. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties
10. Soluble nonantigenic polyethylene glycol-bound enzymes
11. A new procedure for the synthesis of polyethylene glycol-protein adducts
12. Cancer therapy with chemically modified enzymes
13. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins
14. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in the murine meth a sarcoma model
15. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers
16. A water-soluble monitorable peptide and protein crosslinking agent
17. Attachment of drugs to polyethylene glycols
18. Preparation of protein conjugates with alkoxypolyethylene glycols
19. The preparation and properties of novel reversible polymer-protein conjugates
20. Immunotherapy with monomethoxypolyethylene glycol modified allergens
21. PEG activation and ligand binding for the affinity partitioning of proteins in aqueous two-phase systems
22. Suppression of reaginic antibodies
23. Surface modification of proteins: activation of monomethoxypolyethylene glycols by phenylchloroformates
24. Preparation of a Polymer/interleukin-2 Conjugate
25. Succinimidyl carbonates of polyethylene glycol: useful reactive polymers for preparation of protein conjugates
26. Coupling of monomethoxypolyethylene glycols to proteins via active esters
27. Organic synthesis using enzymes in two-phase aqueous ternary polymer systems
28. 4-Phenoxy-35-dinitrobenzoyl polyethylene glycol Reversible attachment of cysteine-containing polypeptides to polymers in aqueous solutions
29. Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site
30. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol
31. An Improved 2,4,6-trinitro benzene sulfonic acid method for the determination of amines
32. Solvent effects on the preferred conformation of poly(ethylene glycols)
33. Conformation of poly(ethylene oxide) in the solid state, melt and solution measured by Raman scattering
34. Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase
35. Modification of amino groups in porcine pancreatic elastase with polyethylene glycol in relation to binding ability towards anti-serum and to enzymic activity
36. Modification of E coli asparaginase with 24-bis(o-methoxypolyethylene glycol)-6-chloro-s-triazine(activated PEG2)
37. Synthesis, isolation and characterization of conjugates of ovalbumin with monomethoxypolyethylene glycol
38. Suppression of reaginic antibodies with modified allergens
39. On-line characterization of polyethylene glycol-modified proteins
40. Selective hepatic uptake of synthetic glycoproteins
41. Preparation properties and applications of carbohydrate conjugates of proteins and lipids
42. Potential use of an asparaginase-dextran conjugate in acute lymphoblastic leukemia
43. Soluble asparaginase-dextran conjugates show increased circulatory persistence and lowered antigen reactivity
44. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran: synthesis and characterization
45. Biopharmaceutical and pharmacological properties
46. Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol
47. Enzymic O-glycosylation of synthetic peptides from sequences in basic myelin protein
48. Primary structural requirements for the enzymatic formation of the N-glycosidic bond in glycoproteins; studies with natural and synthetic peptides
49. Enzymatic N-glycosylation of synthetic Asn-X-Thr containing peptides
50. Preparation and properties of adducts of streptokinase and streptokinase-plasmin complex with polyethylene glycol and pluronic polyol F38
51. Twentyfold increase in alkaline phosphatase activity by sequential reversible activation of the enzyme followed by coupling with a copolymer of ethylene and maleic anhydride
52. Surface modification of proteins by covalent binding of acrylic polymers
53. Chemical modification of interleukin-2 and IFN-beta increases their solubility and extends their plasma half-life
54. Solubilization of Proteins for Pharmaceutical Compositions Using Polymer Conjugation
55. Chemical modification of enzyme molecules to improve their characteristics
56. Physiochemical and biological properties of polyethylene glycol-coupled immunoglobulin G
57. Catalytic activity of administered gulonolactone oxidase polyethylene glycol conjugates
58. Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct
59. Some properties of polyethylene glycol: phenylalanine ammonia-lyase adducts
60. Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes
61. Cancer therapy with chemically modified enzymes
62. Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse
63. Preparation of a polyethylene glycol:superoxide dismutase adduct, and an examination of its blood circulatory life and anti-inflammatory activity
64. Polyethylene glycol-conjugated superoxide dismutase in unilateral lung injury due to re-expansion (re-oxygenation)
65. Chemical basis of drug action
66. Instability of Succinyl ester linkages in O′-monosuccinyl cyclic AMP-protein conjugates at neutral pH
67. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41 000–72 000 daltons)
68. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumor models
69. Chemical modification of interleukin-2 with polymers: A potent drug-delivery system
70. PEGylation of therapeutic proteins - an effective system for drug delivery
71. Acylation of human hemoglobin with polyoxyethylene derivatives
72. Conjugated human hemoglobin as a physiological oxygen carrier-pyridoxalated hemoglobin polyoxyethylene conjugate
73. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats
74. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization
75. Polyethylene glycol modification of Serpins improves therapeutic potential
76. Reduction in immunogenicity and clearance rate of Escherichia colil-asparaginase by modification with monomethoxypolyethylene glycol
77. Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man
78. Enzyme therapy: polyethylene glycol-glucuronidase conjugates as potential therapeutic agents in acid mucopolysaccharidosis
79. Properties of two urate oxidases modified by the covalent attachment of polyethylene glycol
80. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance
81. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
82. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol
83. Antitumor enzyme: polyethylene glycol-modified asparaginase
84. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxypolyethylene glycol modified proteins
85. Polyethylene glycol reactive antibodies in man
86. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
87. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol
88. Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins
89. Suppression of IgE antibodies with conjugates of haptens or allergens and synthetic hydrophilic polymers
90. Specific downregulation of IgE antibodies by tolerogenic conjugates of haptens and allergens with synthetic polymers
91. Suppression of reaginic antibodies with modified allergens
92. Suppression of IgE antibody production in sensitized mice and rats by tolerogenic conjugates of synthetic hydrophilic polymers with antigen or hapten
93. Immunological properties of conjugates of ragweed pollen antigen E with methoxypolyethylene glycol or a copolymer of d-glutamic acid and d-lysine
94. Immunologic properties of conjugates of ragweed antigen E with various alkoxypolyethylene glycols
95. Studies of chemically modified honeybee venom
96. Studies of chemically modified honeybee venom
97. Antibody responses to honey-bee venom and monomethoxy-polyethylene glycol-modified honey-bee venom in mice
98. Effects of polyethylene glycol substitution on enzyme activity
99. Evaluation of three linking chemistries for attaching polyethylene glycol (PEG) to recombinant interleukin-2
100. A comparative study of enzymatic, structural, and pharmacokinetic properties of superoxide dismutase modified by monomethoxyethylene glycol using different methods of coupling
101. Peak for punch, trough for toxicity: the therapeutic index of interleukin-2
102. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2
103. Clinical pharmacology of polyethylene glycol-l-asparaginase
104. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency
105. Two-year double-blind trial of a monomethoxypolyethylene glycol (mPEG) modified grass pollen extract at different dose levels
106. Sterically stabilized liposomes Improvements in pharmacokinetics and antitumor therapeutic efficacy
107. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid
108. Stealth liposomes: An improved sustained release system for 1-beta-arabinofuranosylcytosinc
109. Polyethylene glycol (PEG)-protein conjugates: Application to biomedical and biotechnological processes
110. Ester synthesis catalysed by polyethylene glycol-modified lipase in benzene
111. Polymerization of 10-hydroxydecanoic acid in benzene with polyethylene glycol-modified lipase
112. Chemical modification of horseradish peroxidase with ethanal-methoxypolyethylene glycol: Solubility in organic solvents, activity and properties
113. Targeting of colloidal particles to the bone marrow
114. Non-phagocytic uptake of intravenously injected microspheres in rat spleen
115. The poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow
116. Molecular design for missile drug Synthesis of adriamycin conjugated with immunoglobulin G using polyethylene glycol-block-polyaspartic acid as intermediate carrier
117. Synthesis and carbohydrate-binding activity of polyethylene glycol-Ricinus communis agglutinin I conjugates
118. Preparation of polyethylene glycol-bound NAD and its application in a model enzyme reactor
119. Method to enhance growth and sporulation of pelletized biocontrol fungi